Cargando…
Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study
BACKGROUND: Although initial therapy with a parenteral anticoagulant is required before edoxaban, this strategy is frequently avoided in actual clinical practice because of its complexity. This study assessed the feasibility of edoxaban without initial heparin usage for asymptomatic cancer-associate...
Autores principales: | Nakamura, Michio, Ishiguro, Atsushi, Dazai, Masayoshi, Kawamoto, Yasuyuki, Yuki, Satoshi, Sogabe, Susumu, Hosokawa, Ayumu, Sawada, Kentaro, Muto, Osamu, Izawa, Naoki, Nakashima, Koji, Horie, Yoshiki, Yagisawa, Masataka, Kajiura, Shinya, Ando, Takayuki, Mitsuhashi, Yosuke, Sunakawa, Yu, Kikuchi, Yasuka, Komatsu, Yoshito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757916/ https://www.ncbi.nlm.nih.gov/pubmed/36526992 http://dx.doi.org/10.1186/s12885-022-10403-y |
Ejemplares similares
-
Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
por: Harada, Kazuaki, et al.
Publicado: (2023) -
Report on the excavation of Jemez Cave, New Mexico /
por: Alexander, Hubert G. (Hubert Griggs), 1909-
Publicado: (1935) -
Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study
por: Nakano, Shintaro, et al.
Publicado: (2020) -
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer
por: Nakano, Shintaro, et al.
Publicado: (2022) -
Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)